Initial Evaluation of Vascudyne Coronary Artery Bypass Conduit

Coronary Artery Disease Clinical Trial

— VCAB-1  

Official title:

Initial Evaluation of Vascudyne Coronary Artery Bypass Conduit

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06434935
• Other study ID #: CIP-003
• Status: Enrolling by invitation
• Phase: Early Phase 1
• Start date: November 7, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: June 2024
• Source: Vascudyne, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Vascudyne Coronary Artery Bypass Study (VCAB-1) is an initial safety and feasibility study of the Vascudyne, Inc. Coronary Artery Bypass Conduit (CAB A) for bypass of stenosed native coronary arteries in patients undergoing coronary artery bypass surgery.

Description:

Prospective, non-randomized, initial evaluation clinical study to assess the feasibility of TRUE CAB for secondary coronary targets in patients needing multiple coronary artery bypass. Patients will be implanted with a single TRUE CAB bypass (single proximal and distal anastomoses) to the second or third coronary arteries (CA) bypass target. The primary target CA shall be bypassed using an arterial graft. The left anterior descending (LAD) CA bypass, if needed, shall be bypassed using the left internal mammary artery (LIMA). A saphenous vein shall be used for any additional targets as needed. Estimated enrollment for first three patients (2 weeks), followed by enrollment over 4 months. Follow up through 24 months.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 15
• Est. completion date: December 31, 2025
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients needing isolated coronary artery bypass grafting to multiple coronary arteries (CA) in which the first target CA shall be an arterial bypass to the left anterior descending artery (LAD) and the second and potentially third target CA must be at least 2 mm in diameter, have at least 70% stenosis proximal to the bypass, have at least Thrombolysis in Myocardial Infarction (TIMI) II flow, and shall be among the following options: right coronary artery (RCA), right posterior descending artery (PDA), Ramus Intermedius, obtuse marginal arteries (OM), or diagonal branches of the left anterior descending artery.

2. Male or female patients between the ages of 45 and 75 years inclusive.

3. Elective patient, selected and accepted by the local Heart Team and confirmed by the Sponsor's Screening Committee for an on-pump full sternotomy CABG surgery.

4. Life expectancy of at least 4 years.

5. Female subjects must be of non-childbearing potential, which is defined as post-menopausal (at least 1 year without menses prior to Screening) or documented surgically sterile or post hysterectomy (at least 1 month prior to Screening).

6. Patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent.

7. Patient has been informed and agrees to pre- and post-procedure follow-up, including follow-up cardiac ultrasound and coronary angiogram or computerized tomography (CT) scan.

8. Patient is willing to be compliant with prescribed anticoagulant therapy (critical to preventing thrombus in the investigational device).

Exclusion Criteria:

1. Patients with left ventricular ejection fraction < 35%.

2. Patients with diffusely diseased coronary arteries suggestive of either poor target quality, or poor vessel runoff.

3. Patients requiring emergency surgery.

4. Patients with cardiogenic shock.

5. Patients with any prior open cardiac surgery such as coronary artery bypass graft (CABG).

6. Any planned concomitant cardiac surgery, including but not limited to: valve surgery, repair of intracardiac shunt, surgical arrhythmia ablation.

7. History of cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation.

8. Myocardial infarction (MI) within 21 days or cerebral vascular accident (CVA) within 90 days of the CABG procedure.

9. Patients with Type 1 Diabetes and Patients with Type II Diabetes having glycate hemoglobin test (A1C)>8.

10. Chronic kidney disease with Glomerular Filtration Rate (GFR) < 45 militers per minute (mL/min), or active dialysis patients

11. Moderate to severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume (FEV) <1.5 lit/sec or 45% predicted forced expiratory volume in one second (FEV1).

12. Patient with known interstitial lung disease, diagnosed by imaging or pulmonary function tests, including diffusing capacity of the lungs for carbon monoxide (DLCO).

13. Endocarditis, pericarditis, or any other active systemic infection that would interfere with patient safety.

14. Patient on preoperative anticoagulant (i.e. Warfarin) or any known intrinsic coagulation disorder.

15. Abnormal blood values (e.g. leukopenia, anemia, thrombocytopenia, or thrombocytosis with Platelet Count >400,000 per militer (mL) that could influence graft hemostasis or patient recovery.

16. Known allergies to study device components: Nitinol, Nickel, Titanium, or agents/medication such as contrast agents, antiplatelet therapy, beta-blocker, or statins required for study assessment or optimal post-CABG medical treatment (hospital standard of care).

17. Any medical intervention or condition within the 12 months following TRUE CAB implantation that requires temporary or permanent discontinuation of anticoagulant therapy.

18. History of heparin-induced thrombocytopenia.

19. Contraindication to or known serious allergy to anticoagulant, aspirin, or planned antiplatelet and factor Xa inhibitor therapy.

20. Immunodeficiency including AIDS / HIV, active autoimmune disease, or on immunosuppressant therapy.

21. Treatment with any investigational drug or device within 60 days prior to study entry or ongoing participation in another clinical study of an investigational product.

22. Subject has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance.

23. Has any other condition, in the opinion of the principal investigator, which would put the patient at increased risk from participating in the study or otherwise prevent participation.

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Combination Product:
• CABA
Coronary Bypass

Locations

Country	Name	City	State
Paraguay	Sanatario Italiano	Asunción

Sponsors (1)

Lead Sponsor	Collaborator
Vascudyne, Inc.

Country where clinical trial is conducted

Paraguay, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patency	Intervention-free angiographic patency [failure defined as >50% stenosis or occlusion].	6 months
Primary	Major Adverse Cardiac and Cerebrovascular events (MACCE)	Freedom from MACCE; includes adverse events; death, non-fatal myocardial infraction, non-fatal stroke, unplanned revascularization, and hospitalization due to heart failure	30 days
Secondary	Patency	Intervention-free angiographic patency [failure defined as >50% stenosis or occlusion].	30 days, 12 months, 18 months and 24 months
Secondary	Fitzgibbon classification	Fitzgibbon classification is a grading system for coronary artery bypass grafts (CABGs) that use saphenous vein grafts (SVGs) and arterial grafts to treat severe coronary artery disease. The scale assesses the following characteristics: Fitzgibbon I patency (perfect patency) with no lumen irregularities. Fitzgibbon II patency with lumen irregularities that involve less than 50% of SVG length.; Fitzgibbon III patency with lumen irregularities that involve more than 50% of SVG length	30 days, 6 months and 12 months
Secondary	MACCE	Freedom from MACCE includes adverse events; death, non-fatal myocardial infraction, non-fatal stroke, unplanned revascularization, and hospitalization due to heart failure	6, 12, 18 and 24 months